Pedro C. Barata

4.6k total citations · 1 hit paper
218 papers, 2.5k citations indexed

About

Pedro C. Barata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Pedro C. Barata has authored 218 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Pulmonary and Respiratory Medicine, 99 papers in Oncology and 73 papers in Cancer Research. Recurrent topics in Pedro C. Barata's work include Prostate Cancer Treatment and Research (88 papers), Renal cell carcinoma treatment (66 papers) and Cancer Genomics and Diagnostics (55 papers). Pedro C. Barata is often cited by papers focused on Prostate Cancer Treatment and Research (88 papers), Renal cell carcinoma treatment (66 papers) and Cancer Genomics and Diagnostics (55 papers). Pedro C. Barata collaborates with scholars based in United States, Canada and United Kingdom. Pedro C. Barata's co-authors include Brian I. Rini, Jorge A. García, Oliver Sartor, David S. Hong, Anil K. Sood, Petros Grivas, Channing J. Paller, Vadim S. Koshkin, Moshe Chaim Ornstein and Timothy D. Gilligan and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Investigation.

In The Last Decade

Pedro C. Barata

190 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of renal cell carcinoma: Current status and future directions

2017 622 citations Pedro C. Barata et al. profile →

Peers

Pedro C. Barata

PRM

ONCOL

SURGE

Alessia Cimadamore Italy

Qi Xue China

Veronica Mollica Italy

Ryuichi Mizuno Japan

Chiara Ciccarese Italy

Conor Steuer United States

Bo Dai China

Jean‐Sébastien Frenel France

Nathalie Rioux‐Leclercq France

David Garfield United States

Alessia Cimadamore Italy

Pedro C. Barata

1.3k ×0.9

PRM

841 ×0.8

877 ×1.0

ONCOL

577 ×0.7

824 ×1.6

SURGE

Citations per year, relative to Pedro C. Barata Pedro C. Barata (= 1×) peers Alessia Cimadamore

Countries citing papers authored by Pedro C. Barata

Since Specialization

Citations

This map shows the geographic impact of Pedro C. Barata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro C. Barata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro C. Barata more than expected).

Fields of papers citing papers by Pedro C. Barata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro C. Barata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro C. Barata. The network helps show where Pedro C. Barata may publish in the future.

Co-authorship network of co-authors of Pedro C. Barata

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro C. Barata. A scholar is included among the top collaborators of Pedro C. Barata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro C. Barata. Pedro C. Barata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McKay, Rana R., Shayan Nazari, Andrew Elliott, et al.. (2025). Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. The Oncologist. 30(11).

Jang, Albert, Prateek Jain, Adam Calaway, et al.. (2025). Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?. The Oncologist. 30(9).

Morgans, Alicia K., James C. Jackson, Charles J. Ryan, et al.. (2025). Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.. Journal of Clinical Oncology. 43(5_suppl). 131–131.

Jang, Albert, Jorge A. García, Norbert Avril, et al.. (2024). Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer. Advances in cancer research. 164. 311–358. 2 indexed citations

Kim, Hyung L., Catherine M. Tangen, Ulka N. Vaishampayan, et al.. (2024). SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars and Original Investigations. 42. S4–S4. 2 indexed citations

McKay, Rana R., Pedro C. Barata, Moshe Chaim Ornstein, et al.. (2024). 5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605. The Oncologist. 29(Supplement_1). S13–S13. 1 indexed citations

Pan, Elizabeth, Andrew Elliott, Shankar Siva, et al.. (2024). Characterization of FOLH1 Expression in Renal Cell Carcinoma. Cancers. 16(10). 1855–1855. 1 indexed citations

Barata, Pedro C., et al.. (2024). Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology. 10(7). 975–975. 7 indexed citations

Zarrabi, Kevin, Ulka N. Vaishampayan, & Pedro C. Barata. (2024). Enhancing the Immunogenicity of Nivolumab plus Ipilimumab with Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma. European Urology Focus. 10(6). 879–881.

10.

Nazha, Bassel, Sharon Wu, Jacqueline T. Brown, et al.. (2023). Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers. Cancer. 129(24). 3884–3893. 21 indexed citations

11.

Wei, Shuanzeng, Daniel M. Geynisman, Andrew Elliott, et al.. (2023). Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas. Modern Pathology. 37(2). 100404–100404. 7 indexed citations

12.

Zorko, Nicholas A., et al.. (2023). Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Current Oncology. 30(4). 4246–4256. 21 indexed citations

13.

Fleming, William, Patrick D. Miller, Pedro C. Barata, et al.. (2023). Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. The Prostate. 83(9). 879–885. 4 indexed citations

14.

Jang, Albert, Patrick J. O. Miller, Jodi Lyn Layton, et al.. (2023). Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide. The Prostate. 83(11). 1028–1034. 3 indexed citations

15.

Kasi, Pashtoon Murtaza, Jiemin Liao, Jason S. Starr, et al.. (2023). Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precision Oncology. 7(7). e2300118–e2300118. 8 indexed citations

16.

Jang, Albert, Patrick J. O. Miller, Pedro C. Barata, et al.. (2023). Analysis of TP53 gain of function mutations in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). 246–246. 1 indexed citations

17.

Kopp, Ray Manneh, et al.. (2023). Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT.. Journal of Clinical Oncology. 41(6_suppl). 226–226. 1 indexed citations

18.

Zarrabi, Kevin, et al.. (2023). Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers. 15(5). 1412–1412. 30 indexed citations

19.

Jani, Chinmay, Tian Zhang, Nazlı Dizman, et al.. (2022). Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer. 21(1). 55–62. 2 indexed citations

20.

Marshall, Catherine H., Wei Fu, Hao Wang, et al.. (2021). Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 27(6). 1623–1630. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact